Journal
MOLECULAR BIOTECHNOLOGY
Volume -, Issue -, Pages -Publisher
SPRINGERNATURE
DOI: 10.1007/s12033-023-00710-5
Keywords
Mycobacterium tuberculosis; Molecular modelling; Nucleoid-associated proteins; Inhibitors; Molecular docking; Simulations
Ask authors/readers for more resources
Implementation of computational tools in identifying drug targets for Tuberculosis has shown promise. Nucleoid-Associated Proteins have been found to play a significant role in regulating cellular processes of Mycobacterium tuberculosis, making them potential targets for new drugs. This study used computational methods to identify potential inhibitors for eight Nucleoid-Associated Proteins, and found several FDA-approved drugs as novel targets with therapeutic potential for TB.
Implementation of computational tools in the identification of novel drug targets for Tuberculosis (TB) has been a promising area of research. TB has been a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb) localized primarily on the lungs and it has been one of the most successful pathogen in the history of mankind. Extensively arising drug resistivity in TB has made it a global challenge and need for new drugs has become utmost important.The involvement of Nucleoid-Associated Proteins (NAPs) in maintaining the structure of the genomic material and regulating various cellular processes like transcription, DNA replication, repair and recombination makes significant, has opened a new arena to find the drugs targeting Mtb. The current study aims to identify potential inhibitors of NAPs through a computational approach. In the present work we worked on the eight NAPs of Mtb, namely, Lsr2, EspR, HupB, HNS, NapA, mIHF and NapM. The structural modelling and analysis of these NAPs were carried out. Moreover, molecular interaction were checked and binding energy was identified for 2500 FDA-approved drugs that were selected for antagonist analysis to choose novel inhibitors targeting NAPs of Mtb. Drugs including Amikacin, streptomycin, kanamycin, and isoniazid along with eight FDA-approved molecules that were found to be potential novel targets for these mycobacterial NAPs and have an impact on their functions. The potentiality of several anti-tubercular drugs as therapeutic agents identified through computational modelling and simulation unlocks a new gateway for accomplishing the goal to treat TB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available